Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
- Tablet Terminals Effective for Changing Doctors’ Prescribing Behavior: M3
September 12, 2011
- MTPC Applies for DPP-4 Inhibitor Teneligliptin
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- Ethical Drugs Sales Rise 5.3% in 2nd Quarter: IMS Japan
September 12, 2011
- Market for Anti-RA Drugs to Exceed ¥300 Bil. in 2019: Fuji-Keizai
September 12, 2011
- PIII Trial for Type 2 Diabetes Treatment SYR-472 Started in Japan: Takeda
September 9, 2011
- Afinitor Approved for Pancreatic NET in Europe: Novartis
September 9, 2011
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
- Ogasawara to Become President, Ogawa to Step Down: RDKK
September 6, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…